This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| Follistatin 344 | Larazotide | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved in any form; only human data is from small, completed Phase 1/1-2 AAV gene-therapy trials for muscular dystrophy/myositis, not injectable protein use | Not FDA-approved; Phase 3 celiac disease trial (NCT03569007) terminated in 2022 after interim futility analysis; no active pivotal trial identified |
| Research area | Growth hormone axis, Tissue repair and recovery | Tissue repair and recovery |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | Not reliably established | C32H55N9O10 (free peptide, per PubChem) |
| Molar mass | Not reliably established | Not reliably established |
| CAS number | Not reliably established | 881851-50-9 |
| Registered trials on this site | 2 in the tracker | 5 in the tracker |
| Furthest registered phase | Phase 1 / Phase 2 | Phase 3 |
| Trials currently active | 0 | 0 |
| Trial sponsors | Jerry R. Mendell, Nationwide Children's Hospital | Massachusetts General Hospital, 9 Meters Biopharma, Inc. |
| What is not known | The largest open question for this entry is a category mismatch: essentially all human research on "follistatin-344" used AAV-vectored gene therapy causing a patient's own muscle to manufacture the protein locally over time, not a manufactured protein injected directly and repeatedly the way vendor "Follistatin... | Larazotide's trial record shows an inconsistent efficacy signal: some Phase 1b/2b gluten-challenge and Phase 2 dose-ranging endpoints reportedly reached statistical significance, but the definitive Phase 3 trial for persistent symptoms in celiac disease on a gluten-free diet (NCT03569007) was terminated in 2022 after an interim... |
Full pages: Follistatin 344 and Larazotide. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
